Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo
Open Access
- 22 January 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Translational Psychiatry
- Vol. 3 (1), e223
- https://doi.org/10.1038/tp.2012.142
Abstract
In this study, we characterized early biochemical changes associated with sertraline and placebo administration and changes associated with a reduction in depressive symptoms in patients with major depressive disorder (MDD). MDD patients received sertraline or placebo in a double-blind 4-week trial; baseline, 1 week, and 4 weeks serum samples were profiled using a gas chromatography time of flight mass spectrometry metabolomics platform. Intermediates of TCA and urea cycles, fatty acids and intermediates of lipid biosynthesis, amino acids, sugars and gut-derived metabolites were changed after 1 and 4 weeks of treatment. Some of the changes were common to the sertraline- and placebo-treated groups. Changes after 4 weeks of treatment in both groups were more extensive. Pathway analysis in the sertraline group suggested an effect of drug on ABC and solute transporters, fatty acid receptors and transporters, G signaling molecules and regulation of lipid metabolism. Correlation between biochemical changes and treatment outcomes in the sertraline group suggested a strong association with changes in levels of branched chain amino acids (BCAAs), lower BCAAs levels correlated with better treatment outcomes; pathway analysis in this group revealed that methionine and tyrosine correlated with BCAAs. Lower levels of lactic acid, higher levels of TCA/urea cycle intermediates, and 3-hydroxybutanoic acid correlated with better treatment outcomes in placebo group. Results of this study indicate that biochemical changes induced by drug continue to evolve over 4 weeks of treatment and that might explain partially delayed response. Response to drug and response to placebo share common pathways but some pathways are more affected by drug treatment. BCAAs seem to be implicated in mechanisms of recovery from a depressed state following sertraline treatment.This publication has 73 references indexed in Scilit:
- Metabolite profiling of antidepressant drug action reveals novel drug targets beyond monoamine elevationTranslational Psychiatry, 2011
- Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of conceptTranslational Psychiatry, 2011
- The Neuronal Transporter Gene SLC6A15 Confers Risk to Major DepressionNeuron, 2011
- Nicotine receptors and depression: revisiting and revising the cholinergic hypothesisTrends in Pharmacological Sciences, 2010
- Glycine and a Glycine Dehydrogenase (GLDC) SNP as Citalopram/Escitalopram Response Biomarkers in Depression: Pharmacometabolomics-Informed PharmacogenomicsClinical Pharmacology & Therapeutics, 2010
- Genome-wide association study of major depressive disorder: new results, meta-analysis, and lessons learnedMolecular Psychiatry, 2010
- FiehnLib: Mass Spectral and Retention Index Libraries for Metabolomics Based on Quadrupole and Time-of-Flight Gas Chromatography/Mass SpectrometryAnalytical Chemistry, 2009
- Human gut microbiome adopts an alternative state following small bowel transplantationProceedings of the National Academy of Sciences of the United States of America, 2009
- Antidepressant specificity of serotonin transporter suggested by three LeuT–SSRI structuresNature Structural & Molecular Biology, 2009
- Deletion of v7-3 (SLC6A15) transporter allows assessment of its roles in synaptosomal proline uptake, leucine uptake and behaviorsBrain Research, 2007